Chemistry:Fosdagrocorat
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | PF-04171327; PF-4171327; Dagrocorat 2-(dihydrogen phosphate); Dagrocorat dihydrogen phosphate |
| Drug class | Selective glucocorticoid receptor modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H30F3N2O5P |
| Molar mass | 574.537 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fosdagrocorat (developmental code names PF-04171327 and PF-4171327; also known as dagrocorat 2-(dihydrogen phosphate)) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed.[1][2][3][4] It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics.[5][6] The drug reached phase II clinical trials prior to the discontinuation of its development.[1][3][4]
See also
References
- ↑ 1.0 1.1 "Fosdagrocorat - AdisInsight". http://adisinsight.springer.com/drugs/800029004.
- ↑ International Nonproprietary Names for Pharmaceutical Substances (INN)
- ↑ 3.0 3.1 "Development of nonsteroidal glucocorticoid receptor modulators based on N-benzyl-N-(4-phenoxyphenyl)benzenesulfonamide scaffold". Bioorg. Med. Chem. 25 (13): 3461–3470. 2017. doi:10.1016/j.bmc.2017.04.032. PMID 28506584.
- ↑ 4.0 4.1 "Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis". Expert Opin Investig Drugs 26 (2): 187–195. 2017. doi:10.1080/13543784.2017.1276562. PMID 28043173.
- ↑ "Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects". Int J Clin Pharmacol Ther 54 (12): 966–976. 2016. doi:10.5414/CP202659. PMID 27781421.
- ↑ "Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study". Int J Rheum Dis 20 (8): 960–970. 2017. doi:10.1111/1756-185X.13053. PMID 28328159.
External links
 |  |
